Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Rhodia To Bolster Bulk Acetaminophen Business With BASF Asset Purchase

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

French specialty chemicals firm Rhodia has purchased BASF's acetaminophen business as part of a strategy to reinforce its bulk analgesic operations, the company announced Nov. 5

You may also be interested in...



Ibuprofen ANDA

BASF receives FDA approval of ANDA 75-661 for ibuprofen 200 mg Dec. 12. German chemical firm, which recently its divested acetaminophen assets, claims to be world's largest ibuprofen producer (1"The Tan Sheet" Nov. 12, p. 7)...

Ibuprofen ANDA

BASF receives FDA approval of ANDA 75-661 for ibuprofen 200 mg Dec. 12. German chemical firm, which recently its divested acetaminophen assets, claims to be world's largest ibuprofen producer (1"The Tan Sheet" Nov. 12, p. 7)...

Ibuprofen ANDA

BASF receives FDA approval of ANDA 75-661 for ibuprofen 200 mg Dec. 12. German chemical firm, which recently its divested acetaminophen assets, claims to be world's largest ibuprofen producer (1"The Tan Sheet" Nov. 12, p. 7)...

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS093268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By